Not Signed In - Pictures
aa1 tab5 gif
with management of metastatic prostate cancer should be resolved in the near future The next decade should provide us with new weapons by which to attack and defeat prostate cancer This study was supported by grant 1 P50 CA69568 from the Specialized Program of Research Excellence of the National Cancer Institute Bethesda Md References
aa1 fig2 gif
of monotherapy vs CAB reported little difference between the two groups 14 Given the conflicting data the benefit of CAB remains unclear Ongoing studies should clarify this issue Early or Delayed Endocrine Therapy Determining the most effective timing of endocrine treatment of prostate cancer remains controversial Endocrine therapy is the mainstay of
aa1 fig1 gif
eg increases in platelet aggregation low density lipoprotein and certain clotting factors that may result in thromboembolic sequelae have tempered enthusiasm for the use of estrogens Acute administration of the LHRH analogs stimulates the secretion of LH in the pituitary gland Conversely chronic administration suppresses LH secretion by the down regulation of
email this page
print this page
bookmark this page
feedback on this page
